Management of Wheezing in a 16‑Month‑Old Child

Assessment and Differential Diagnosis

In a 16‑month‑old, absence of respiratory distress is defined by a respiratory rate < 50 breaths/min, heart rate < 140 beats/min, no use of accessory muscles, and the ability to feed normally. [1][2]
The evaluation should rule out alternative causes such as foreign‑body aspiration, bronchiolitis (first episode with viral illness), tracheomalacia, vascular ring, or other structural airway abnormalities. [2][3]4
Viral respiratory infections are the most common trigger of wheeze in this age group, and many children improve with asthma‑directed therapy even when a formal asthma diagnosis is not yet established. [1][5]

Administer albuterol (salbutamol) as a nebulized dose of 2.5 mg or via metered‑dose inhaler with spacer (100 µg per actuation, up to 10 actuations) for mild symptoms. 6
Children younger than 4 years tolerate a face mask attached to a nebulizer or a valved holding chamber better than other delivery devices. [1][5]

High‑risk frequent wheezers – ≥ 4 wheezing episodes in the past year lasting > 1 day, affecting sleep, and a positive asthma predictive index (API). [1][5]
- A positive API is met by either:
  - Parental history of asthma or physician‑diagnosed atopic dermatitis or documented aero‑allergen sensitization; or
  - Two of the following: food sensitization, peripheral blood eosinophilia > 4 %, or wheezing episodes occurring apart from colds. [1][5]
Persistent symptoms – need for rescue bronchodilator > 2 days per week for > 4 weeks. [1][5]
Recurrent exacerbations – ≥ 2 courses of systemic corticosteroids within the previous 6 months. [1][5]

Low‑dose inhaled corticosteroid (ICS) is first‑line; budesonide nebulizer solution is FDA‑approved for ages 1–8 years, and montelukast granules are approved down to 1 year. [1][5]
The modest, non‑progressive reduction in growth velocity associated with low‑dose ICS is outweighed by the clinical benefits. [1][5]
Alternative agents (montelukast or cromolyn) may be considered when ICS are contraindicated, but they remain secondary to ICS. [2][3]8

Provide as‑needed bronchodilator only for symptom relief. [1][2]
Consider intermittent short‑course ICS during high‑risk periods (e.g., viral season) if a clear seasonal pattern of exacerbations exists. [1][5]

Re‑evaluate therapeutic response 4–6 weeks after initiation; lack of clear benefit should prompt reconsideration of diagnosis or alternative treatments. 8
Once asthma control is achieved and maintained for ≥ 3 months, a step‑down of therapy is recommended. 8
Caregiver education should cover correct inhaler/spacer technique, avoidance of tobacco smoke, and recognition of worsening symptoms. 1
Provide a written action plan for home management of acute exacerbations. 7

Approximately two‑thirds of children who are frequent wheezers and have a positive API will develop persistent asthma throughout childhood; early identification and treatment can reduce long‑term morbidity. [1][5]
Most young children with viral‑induced wheeze experience remission by age 6 years; prolonged unnecessary therapy should be avoided in the absence of risk factors. [1][5]
In children with persistent wheeze despite appropriate bronchodilator and ICS therapy, structural airway abnormalities are found in about 33 % of cases; flexible bronchoscopy should be considered. 4

For a 16‑month‑old without respiratory distress, the immediate priority is symptomatic relief with an as‑needed bronchodilator while a detailed history (episode frequency, triggers, atopic features, family history) is obtained to determine whether controller therapy is warranted. [1][2]5